CA19-9 guided salvage treatment after pancreatic cancer resection: a prospective clinical study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024288

Enrollment

Unknown

Registered

2019-07-05

Start date

2019-07-15

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

single arm:Salvage treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Histologically confirmed pancreatic adenocarcinoma, curative resection received; 3. Have received or is receiveing adjuvant therapy (gemcitabine + S-1/capecitabine); 4. CA19-9 elevation greater than the normally used upper limit (37 U/mL) with an increase over 50% and recurrence is not found by enhanced CT; 5. KPS>60, ECOG:0-2; 6. Comprehensive and detailed data, ability to comply with tumor marker analysis and radiological examination; 7. Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1.Pancreatic endocrine tumor; 2.Metastatic disease; 3.Other malignant tumors; 4.Lewis antigen negative; 5.Pregnant or nursing; 6.Attend other clinical trials.

Design outcomes

Primary

Measure	Time frame
overall survival;Disease-free Survival;1-year Disease-free Survival;	—

Countries

China

Contacts

Public ContactChunmei Bai

Peking Union Medical College Hospital

baichunmei1964@163.com+86 010-69158530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026